Home › Compare › ALVRQ vs ABBV
ALVRQ yields 2000000.00% · ABBV yields 3.06%● Live data
📍 ALVRQ pulled ahead of the other in Year 1
Combined, ALVRQ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ALVRQ + ABBV for your $10,000?
Alvarion Ltd. provides autonomous Wi-Fi network products worldwide. The company designs solutions for carrier Wi-Fi, enterprise connectivity, smart city, smart hospitality, and connected campuses and events. It offers BreezeACCESS, a wireless broadband access solution for license-exempt frequencies; BreezeMAX Extreme, a WiMAX 16e wireless broadband technology; BreezeNET, a point-to-point and point-to-multipoint networking solution for connecting buildings, campuses, industrial zones, and remote sites; and BreezeULTRA, a family of wireless broadband products that operate in the 4.95.9 GHz unlicensed frequency band. The company also provides WBS and WBSn, which are carrier-grade outdoor Wi-Fi base stations; WBSac, a carrier-grade Wi-Fi solution for buildings, workplaces, universities, schools, hospitals, hotels, and large stores; Arena Controller, a Wi-Fi cloud controller that acts as mediation device between the operator's control core and the Wi-Fi infrastructure; and Star Management Suite, a set of carrier-class tools, which support the wireless broadband life-cycle - from initial installation to full service provision, and ongoing maintenance and support activities. It serves carriers, local governments, and hospitality sectors. The company was formerly known as BreezeCOM Ltd. and changed its name to Alvarion Ltd. as result of merger with Floware Wireless Systems Ltd. in August 2001. The company was founded in 1992 and is headquartered in Herzliya, Israel. Alvarion Ltd. is a subsidiary of SuperCom Ltd.
Full ALVRQ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.